Skip to content

Study · Randomized controlled trial · n = 20 · 1996

5 results

The role of DDAVP (desmopressin) in orthognathic surgery.

Guyuron B, Vaughan C, Schlecter B

Annals of plastic surgery1 Nov 1996Cited by 25 (Europe PMC)

PMID8937605 (opens in a new tab)DOI10.1097/00000637-199611000-00010 (opens in a new tab)PepBankPUB-08937605
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In bimaxillary osteotomy patients, average blood loss was 144 ml less with DDAVP than without DDAVP (p < 0.50).

    In plain wordsIn bimaxillary osteotomy patients, blood loss was 144 ml less with DDAVP than without DDAVP.

    Peptide
    Desmopressin
    Outcome
    DecreaseBlood loss
    Study

    n = 20

    Comparator
    No DDAVP
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 micrograms · infusionAs given in this study (human).

    Measurements

    Blood loss difference (group I less than group II)
    144 ml
    DDAVP group versus no-DDAVP group, per patient average

    Source sentences

    Summary
    On average, the blood loss in group I patients was 144 ml less per patient than group II patients (p < 0.50).
    3 context sentences
    Summary · context
    Twenty patients, 15 females and 5 males, undergoing bimaxillary osteotomy were randomized into two groups of ten.
    Summary · context
    Perioperatively, group 1 patients received 20 micrograms of DDAVP infused over one-half hour.
    Summary · context
    Group II patients did not receive DDAVP.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In bimaxillary osteotomy patients, 2 of 10 DDAVP recipients lost over 750 ml versus the reported 6 to 10 controls (p < 0.20).

    In plain wordsIn bimaxillary osteotomy patients, fewer DDAVP recipients lost over 750 ml than controls.

    Peptide
    Desmopressin
    Outcome
    DecreaseBlood loss exceeding 750 ml
    Study

    n = 20

    Comparator
    No DDAVP
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 micrograms · infusionAs given in this study (human).

    Measurements

    Patients with blood loss over 750 ml
    2 patients
    group I (DDAVP), 10 patients
    Patients with blood loss over 750 ml
    6 to 10 patients
    group II (no DDAVP), reported as '6 to 10' of 10

    Source sentences

    Summary
    Only 2 of 10 patients in group I lost in excess of 750 ml, while 6 to 10 group II patients experienced blood loss greater than 750 ml (p < 0.20).
    3 context sentences
    Summary · context
    Twenty patients, 15 females and 5 males, undergoing bimaxillary osteotomy were randomized into two groups of ten.
    Summary · context
    Perioperatively, group 1 patients received 20 micrograms of DDAVP infused over one-half hour.
    Summary · context
    Group II patients did not receive DDAVP.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In bimaxillary osteotomy patients, hematocrit decline was smaller with DDAVP than without DDAVP (6.17 versus 11.61, p < 0.01).

    In plain wordsIn bimaxillary osteotomy patients, hematocrit decreased less with DDAVP than without DDAVP.

    Peptide
    Desmopressin
    Outcome
    DecreaseHematocrit decline versus control
    Study

    n = 20

    Comparator
    No DDAVP
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 micrograms · infusionAs given in this study (human).

    Measurements

    Postoperative hematocrit drop
    6.17 hematocrit (unit not stated)
    group I (DDAVP)
    Postoperative hematocrit drop
    11.61 hematocrit (unit not stated)
    group II (no DDAVP)

    Source sentences

    Summary
    When collated, this hematocrit drop of 11.61 for group II and 6.17 for group I (recipients of DDAVP) proved to be significantly different (p < 0.01).
    3 context sentences
    Summary · context
    Twenty patients, 15 females and 5 males, undergoing bimaxillary osteotomy were randomized into two groups of ten.
    Summary · context
    Perioperatively, group 1 patients received 20 micrograms of DDAVP infused over one-half hour.
    Summary · context
    Group II patients did not receive DDAVP.
  4. 04HumanNon-randomized trialEfficacy outcome

    In bimaxillary osteotomy patients receiving DDAVP, postoperative hematocrit dropped by 6.17 of the preoperative mean (p < 0.001).

    In plain wordsIn bimaxillary osteotomy patients receiving DDAVP, postoperative hematocrit decreased from its preoperative value.

    Peptide
    Desmopressin
    Outcome
    DecreasePostoperative hematocrit decline
    Study

    n = 10

    Comparator
    Preoperative mean hematocrit
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    20 micrograms · infusionAs given in this study (human).

    Measurements

    Postoperative hematocrit decline
    6.17
    DDAVP group versus preoperative mean; scale not specified in abstract

    Source sentences

    Summary
    The average postoperative hematocrit for patients in group I dropped by 6.17 of the preoperative mean hematocrit (p < 0.001).
    3 context sentences
    Summary · context
    Twenty patients, 15 females and 5 males, undergoing bimaxillary osteotomy were randomized into two groups of ten.
    Summary · context
    Perioperatively, group 1 patients received 20 micrograms of DDAVP infused over one-half hour.
    Summary · context
    Group II patients did not receive DDAVP.
  5. 05HumanNon-randomized trialSafety outcome

    In bimaxillary osteotomy patients, no significant adverse side effects of desmopressin acetate were observed.

    In plain wordsIn bimaxillary osteotomy patients, no significant adverse side effects of desmopressin were observed.

    Peptide
    Desmopressin
    Outcome
    Not applicableAdverse side effects
    Study

    n = 10

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 micrograms · infusionAs given in this study (human).

    Source sentences

    Summary
    No significant adverse side effects of desmopressin acetate were observed.
    3 context sentences
    Summary · context
    Twenty patients, 15 females and 5 males, undergoing bimaxillary osteotomy were randomized into two groups of ten.
    Summary · context
    Perioperatively, group 1 patients received 20 micrograms of DDAVP infused over one-half hour.
    Summary · context
    Group II patients did not receive DDAVP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.